Aleglitazar is primarily investigated for its potential in managing type 2 diabetes by improving insulin sensitivity and glucose metabolism. It acts as a dual agonist for peroxisome proliferator-activated receptors (PPARs), targeting both PPAR-alpha and PPAR-gamma, which play key roles in lipid and glucose regulation. This dual action helps in reducing blood sugar levels and improving lipid profiles, making it a promising candidate for diabetic patients with associated dyslipidemia. Additionally, its anti-inflammatory properties may offer benefits in reducing cardiovascular risks, which are often elevated in diabetic individuals. However, its development was discontinued due to safety concerns, particularly related to kidney and heart complications. Despite this, research on its mechanism continues to provide insights into PPAR-targeted therapies for metabolic disorders.